-
$39.95
-
1 mg
Description
This scholarly article reviews the current state of evidence regarding the use of cannabidiol CBD for treating nonmotor symptoms associated with Parkinsons disease Including conditions such as psychosis REMsleep behavioral disorder mood issues and overall impact on patient stigmatization due to illness presentation Findings indicate promising yet inconclusive outcomes across several pilot investigations warrant further validation through larger scale randomized control trials focusing particularly upon longerterm usage patterns and comprehensive monitoring strategies surrounding both effectiveness metrics alongside possible negative health consequences over time periods extending beyond initial observation windows currently documented within existing literature sources referenced herein.